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A B S T R A C T
Purpose
Older adults are at increased risk for chemotherapy toxicity, and standard oncology assessment
measures cannot identify those at risk. A predictive model for chemotherapy toxicity was developed
(N = 500) that consisted of geriatric assessment questions and other clinical variables. This study
aims to externally validate this model in an independent cohort (N = 250).
Patients and Methods
Patients age $ 65 years with a solid tumor, fluent in English, and who were scheduled to re-
ceive a new chemotherapy regimen were recruited from eight institutions. Risk of chemotherapy
toxicity was calculated (low, medium, or high risk) on the basis of the prediction model before
the start of chemotherapy. Chemotherapy-related toxicity was captured (grade 3 [hospitalization
indicated], grade 4 [life threatening], and grade 5 [treatment-related death]). Validation of the
prediction model was performed by calculating the area under the receiver-operating characteristic
curve.
Results
The study sample (N = 250) had a mean age of 73 years (range, 65 to 94 [standard deviation, 5.8]).
More than one half of patients (58%) experienced grade$ 3 toxicity. Risk of toxicity increased with
increasing risk score (36.7% low, 62.4% medium, 70.2% high risk; P , .001). The area under the
curve of the receiver-operating characteristic curve was 0.65 (95% CI, 0.58 to 0.71), which was not
statistically different from the development cohort (0.72; 95% CI, 0.68 to 0.77; P = .09). There was
no association between Karnofsky Performance Status and chemotherapy toxicity (P = .25).
Conclusion
This study externally validated a chemotherapy toxicity predictivemodel for older adults with cancer.
This predictive model should be considered when discussing the risks and benefits of chemo-
therapy with older adults.
J Clin Oncol 34:2366-2371. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Approximately 60% of all cancers and 70% of
cancer mortality occurs in individuals age $ 65
years, defining cancer as a disease of older adults.1
Chemotherapy remains a standard component of
cancer treatment. The literature is replete with
studies that demonstrate that older adults expe-
rience similar chemotherapy efficacy; however,
these patients are also at increased risk for che-
motherapy toxicity compared with younger
adults.2-4 Furthermore, older adults are less likely
to be offered chemotherapy because of concerns
about their capacity to endure treatment.5,6 To
make personalized treatment decisions and to
anticipate serious adverse effects, it is important
to identify those older adults who are at risk.
Conventional oncology performance status
measures, such as the Karnofsky Performance
Status (KPS)7 or the Eastern Cooperative Oncology
Group performance status,8 are used in patients
with cancer to predict treatment toxicity and
survival, regardless of age9-11; however, it is not
clear if they are valid predictors of toxicity, espe-
cially in older adults, as these tools were validated
in younger adults and do not address the diversity
in health status of the older cancer population.
Instead, it has been widely recognized that in-
corporating geriatric assessment tools can identify
areas of vulnerability beyond chronologic age by
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providing an evaluation of functional status, cognition, nutrition,
social support, psychological state, comorbidity, and medications.12,13
A validated tool to assess chemotherapy toxicity risk in older adults
with cancer is needed.14
To determine the utility of a geriatric assessment in antici-
pating chemotherapy toxicity in older adults with cancer, a pro-
spective study of 500 older adults with cancer was previously
conducted. A predictive model for chemotherapy toxicity was
developed that consisted of 11 questions, including factors ob-
tained in everyday oncology practice—patient age, number of
chemotherapy drugs, dosing, and laboratory values—and factors
not typically used in everyday oncology practice—geriatric as-
sessment questions.2 The model identified older adults at risk for
chemotherapy toxicity, whereas the commonly used measure of
performance status in oncology practice, KPS, did not. The model
was internally validated using a 10-fold validation process. The aim
of this study is to externally validate the predictive model in an
independent cohort of older adults. This study fills a gap in the
literature by providing evidence of external validation, which is
needed to demonstrate generalizability of results and support
translation of research into practice.
PATIENTS AND METHODS
The chemotherapy toxicity prediction model was developed from data
collected in a prospective longitudinal study of 500 patients age$ 65 years.
Study methods and derivation of the toxicity model have been previ-
ously described.2 A prediction model that consisted of 11 prechemo-
therapy variables—geriatric assessment questions, laboratory values, tumor
characteristics, planned treatment, and age—was developed (Table 1). In
the prediction model, risk scores were assigned to each variable. Total risk
score ranged from 0 (lowest toxicity risk) to 19 (highest toxicity risk). The
cohort was divided into three categories on the basis of this risk score: low
risk (0 to 5 points), medium risk (6 to 9 points), and high risk (10 to
19 points). The treating team was blind to the calculated risk score and
category of the patient.
In this article, external validation of this predictive model is de-
scribed. Between April 2008 and October 2012, 250 patients age$ 65 years
were recruited at eight institutions—six participated in the development
study; two new sites participated in the validation cohort—across the
United States. Eligibility criteria were age$ 65 years, diagnosis of any type
of solid tumor, scheduled to receive a new chemotherapy regimen, and
fluent in English (because all geriatric assessment measures were not
validated in other languages). Patients completed the informed consent
process to participate. This study was approved by the institutional review
board at each participating institution.
Study procedures for the validation cohort were identical to those
used in the development cohort. Patients completed a prechemotherapy
geriatric assessment that captured socio-demographics, tumor and
treatment variables, laboratory test results, and geriatric assessment
domains. Patients were observed through the chemotherapy course and
grade 3 (hospitalization indicated), grade 4 (life-threatening), and grade
5 (treatment-related death) adverse events, as defined by the National
Cancer Institute Common Terminology Criteria for Adverse Events,
version 3.0, were captured by chart review.15 Two physicians reviewed
toxicities and concurred that they were attributable to chemotherapy.
Routine blood counts checked between chemotherapy cycles were not
included as hematologic toxicity. Hematologic toxicity was only con-
sidered to be attributable to chemotherapy if blood counts were checked
because the patient was symptomatic and sought medical attention or if
low blood counts led to a delay or modification on the day of scheduled
treatment.
Statistical Analyses
Baseline characteristics of patients in the development and validation
cohorts were tabulated and compared by using x2 statistics for categori-
cal variables and by two-sampled t tests for continuous variables. National
Cancer Institute Common Terminology Criteria for Adverse Events,
version 3.0, was used to capture grade 3 to 5 hematologic andnonhematologic
toxicity.15
A chemotherapy toxicity score was calculated for each individual
patient in the validation cohort by using the 11 prechemotherapy variables
that were included in the predictive model for chemotherapy toxicity
derived from the development cohort. Patients were categorized as being at
low, intermediate, or high risk of toxicity on the basis of specified cut
points. Observed grade 3 to 5 toxicity rates between groups were compared
by using a x2 test of proportions. This distribution of toxicity over the
different risk groups was compared with the ability of KPS to predict
toxicity. For this, KPS scores were divided into three groups (90 to 100, 80,
and # 70) and differences were likewise assessed by using a x2 test of
proportions. We assessed the validity of the model by composing receiver-
operating characteristic (ROC) curves and calculating the area under the
curve (also known as C-statistic) for the prediction model and KPS
scores.16 Areas under the curve were compared by using the Delong
nonparameteric approach.17
For approximately 80% power to detect a substantial difference in
model performance, the validation sample had to include a minimum of
100 patients with and 100 patients without the study endpoint.18 This
assumed that approximately 50% of patients had experienced at least one
grade 3 to 5 toxicity, which is consistent with data from the development
cohort. We thus increased the sample size of this validation cohort to
250 patients to exceed 80% power.
All analyses were performed in SAS (Version 9.2; SAS Institute, Cary,
NC). All tests were two-sided, and a P value of , .05 was considered
statistically significant.
Table 1. Prediction Model and Scoring Algorithm for Chemotherapy Toxicity
Variable Value/Response Score
Age of patient $ 72 years 2
, 72 years 0
Cancer type GI or GU cancer 2
Other cancer types 0
Planned chemotherapy dose Standard dose 2
Dose reduced upfront 0
Planned No. of chemotherapy
drugs
Polychemotherapy 2
Monochemotherapy 0
Hemoglobin , 11 g/dL (male), , 10 g/dL
(female)
3
$ 11 g/dL (male), $ 10 g/dL
(female)
0
Creatinine clearance (Jeliffe,
ideal weight)
, 34 mL/min 3
$ 34 mL/min 0
How is your hearing (with
a hearing aid, if needed)?
Fair, poor, or totally deaf 2
Excellent or good 0
No. of falls in the past
6 months
$ 1 3
None 0
Can you take your own
medicine?
With some help/unable 1
Without help 0
Does your health limit you
in walking one block?
Somewhat limited/limited a lot 2
Not limited at all 0
During the past 4 weeks, how
much of the time has your
physical health or emotional
problems interfered with your
social activities (like visiting
with friends, relatives, etc)?
Limited some of the time, most of
the time, or all of the time
1
Limited none of the time or a little
of the time
0
NOTE. See Hurria et al.2
Abbreviation: GI, gastrointestinal; GU, genitourinary.
www.jco.org © 2016 by American Society of Clinical Oncology 2367
Hurria et al
RESULTS
Patient, Tumor, and Treatment Characteristics
Table 2 includes patient characteristics for the development and
validation cohorts. Mean age for participants in the development
cohort was 73.1 years (standard deviation [SD], 6.2) and 73.0 years
(SD, 5.8) in the validation cohort (P = .78); 56% of patients in the
development cohort were female compared with 55% in the validation
cohort (P = .79). Significant differences between the two cohorts were
observed for cancer type and stage. In the development cohort, more
patients had gynecologic cancers (17% in the development cohort v
7% in the validation cohort), whereas in the validation cohort, breast
cancer was more prevalent (11% in the development cohort v 24% in
the validation cohort; P, .001). In addition, the development cohort
included more patients with metastatic disease compared with
the validation cohort (P = .02). There were no significant dif-
ferences between the two cohorts regarding the following
treatment characteristics: receiving the standard dose of che-
motherapy (per National Comprehensive Cancer Network
guidelines), receiving polychemotherapy (a multidrug regimen),
line of therapy (first line or greater than first line), and use of
growth factors.
Geriatric assessment variables and laboratory values are
presented in Table 3. The development cohort reported a slightly
higher level of social activity (development cohort: mean, 56.2 [SD,
22.8]; validation cohort: mean, 60.3 [SD, 21.8]; P = .02). All other
geriatric assessment characteristics showed no significant differ-
ences between the two cohorts (Table 3). Mean physician-rated
KPS was 84.7 (SD, 11.4) and 85.8 (SD, 13.0) for the development
and validation cohorts, respectively (P = .50). Of patients in the
development cohort, 56% had abnormal liver function tests
compared with 26% in the validation cohort (P , .001). There
were no statistically significant differences in other laboratory
variables between the two cohorts.
Chemotherapy Toxicity
More than one half of patients in the validation cohort (58%)
experienced grade 3 to 5 toxicity compared with 53% of patients in
the development cohort (Table 4). Of patients in the validation
cohort, 34% experienced hematologic toxicity and 55% experi-
enced nonhematologic toxicity. The most frequent hematologic
toxicities were grade 3 absolute neutrophil count (12%) and grade
3 anemia (7%). The most frequent nonhematologic toxicities were
grade 3 fatigue (20%) and grade 3 infections (10%). Of patients in
both the development and validation cohorts, 2% died as a result of
chemotherapy toxicity.
Model Validation
Risk score ranges from 0 to 19 points and was divided into
three groups (low, 0 to 5 points; medium, 6 to 9 points; high, 10 to
19 points). Most patients (53%) were classified as intermediate
risk, 24% of patients were classified as low risk, and 23% were
classified as high risk. In the development cohort, risk of toxicity
increased with increasing risk score (Fig 1). In the validation
cohort, the increase in toxicity risk with increasing risk score was
slightly attenuated but statistically significant (36.7% in the low-
risk group, 62.4% in the medium-risk group, and 70.2% in the
high-risk group; P , .001; Fig 1). Area under the ROC curve for
the predictive model in the validation cohort (0.65 [95% CI, 0.58
to 0.71]) was not statistically different from the development
cohort (0.72 [95% CI, 0.68 to 0.77]; P = .09; Appendix Fig A1,
online only).2
Physician-rated KPS was not predictive of chemotherapy
toxicity in either the development cohort (P = .19) or the validation
cohort (P= .25). Area under the ROC curve for KPSwas 0.54 (95%CI,
Table 2. Patient and Treatment Characteristics: Development and Validation
Cohorts
Characteristic
Development
Cohort
Validation
Cohort P
Patient
Age, years .78
65-69 175 (35) 86 (34)
70-74 127 (25) 67 (27)
75-79 105 (21) 60 (24)
80-84 73 (15) 30 (12)
$ 85 20 (4) 7 (3)
Mean (SD) 73 (6) 73 (6)
Sex .79
Female 281 (56) 138 (55)
Male 219 (44) 112 (45)
Cancer type , .01
Breast 57 (11) 59 (24)
Lung 143 (29) 64 (26)
GI 135 (27) 68 (27)
GYN 87 (17) 18 (7)
GU 50 (10) 30 (12)
Other 28 (6) 11 (4)
Cancer stage .02
I 23 (5) 10 (4)
II 59 (12) 40 (16)
III 111 (22) 68 (27)
IV 307 (61) 129 (52)
Other 0 (0) 3 (1)
Education .41
Less than high school 18 (4) 14 (6)
High school graduate 175 (35) 82 (33)
Associate/bachelor’s
degree
202 (40) 109 (44)
Advanced degree 104 (21) 45 (18)
Missing 1 (0) 0 (0)
Race .01
White 426 (85) 206 (82)
Black 42 (8) 20 (8)
Asian 26 (5) 10 (5)
Other 6 (1) 14 (6)
Treatment
Standard dose .90
No 120 (24) 61 (24)
Yes 380 (76) 189 (76)
No. of chemo drugs .96
Monochemotherapy 149 (30) 74 (30)
Polychemotherapy 351 (70) 176 (70)
Line of chemotherapy .86
First line 355 (71) 176 (70)
. First line 145 (29) 74 (30)
Growth factor use .75
No 294 (59) 144 (58)
Yes 206 (41) 106 (42)
NOTE. Data are given as No. (%) unless otherwise noted.
Abbreviations: SD, standard deviation; GI, gastrointestinal; GYN, gynecologic;
GU, genitourinary.
2368 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Predicting Chemotherapy Toxicity in Older Adults
0.48 to 0.61) for the validation cohort compared with 0.53 (95%CI,
0.48 to 0.57) for the development cohort.2 The C-statistic for
KPS was 0.54 (95% CI, 0.48 to 0.61), which is statistically
significantly smaller than the C-statistic for the predictive model
(P = .02).
DISCUSSION
This study confirms that the risk of chemotherapy toxicity is high
in older adults with cancer, with more than one half of all patients
experiencing grade 3 to 5 toxicity. In both the development and
validation cohorts, this model had a greater ability to discrim-
inate toxicity risk in older adults than did the present standard
oncologic assessment of performance status, the KPS score.
Weighing the risks and benefits of chemotherapy in older adults is
challenging as there are few older adults included in randomized
clinical trials to inform this risk. Furthermore, those older adults
who are included in clinical trials are physically fit and not
representative of the general older population.19,20 Hence, this
study fills a gap in knowledge by developing a validated tool to
assess chemotherapy toxicity risk among older adults who receive
chemotherapy in everyday practice to aid in clinical decision
making.
The high risk of chemotherapy toxicity demonstrated in this
study is consistent with previous studies2-4 and can be explained by
several factors. First, physiologic reserves in all organ systems decrease
with age, whichmay influence the capacity to endure treatment. Aging
is associated with decreased bone marrow reserve and an increased
risk of chemotherapy-related myelosuppression.21,22 In addition,
clearance of chemotherapy can be influenced by impaired renal
function, which is highly prevalent in older adults.23 Furthermore,
practical issues may influence adherence to supportive care. For
example, patients with a poor support system may be less able to
seek medical attention when they experience adverse effects.
Patients with impaired hearing or cognitive impairment may not
have understood how to take their supportive care medications or
when to seek attention if they develop a treatment-related adverse
effect.
Therefore, identifying areas of vulnerability before the start of
treatment is essential. A geriatric assessment can be used for this
purpose13,24 and has been shown to be feasible in oncologic
practices and clinical trials.25 In addition, several studies have
suggested that findings from the geriatric assessment influence
treatment decisions in 20% to 50% of patients.26 The In-
ternational Society for Geriatric Oncology and the National
Comprehensive Cancer Network therefore advises performing at
least a screening geriatric assessment in all older adults with
cancer.13,24
Other chemotherapy risk scores have been developed for
older adults with cancer. For example, the Chemotherapy Risk
Assessment Scale for High-Age Patients was also developed in
a population of older adults with cancer and predicts grade 4 hema-
tologic or grade 3 to 4 nonhematologic toxicity on the basis of
clinical and geriatric assessment variables.3 This model was de-
veloped (N= 331; ROC, 0.65) and validated (N= 187; ROC, 0.64) in
older adults with cancer. Variables predicting grade 4 hematologic
toxicity were diastolic blood pressure, instrumental activity of daily
living score, lactate dehydrogenase, and estimated toxicity of the
chemotherapy regimen on the basis of the MAX2 score. Variables
predicting grade 3 and 4 nonhematologic toxicity were Eastern
Cooperative Oncology Group performance status, mini-mental
health status, mini-nutritional assessment, and the MAX2 score.
A main difference between these two predictive models is that we
sought to identify specific questions that were predictive of che-
motherapy toxicity risk, rather than full measures, to increase the
ease of calculation and scoring.
This study has some important limitations. Although the
model was able to discriminate toxicity risk better than KPS, it was
less able to discriminate between moderate and high-risk toxicity
than we expected on the basis of the development study. Therefore,
the tool may be best used in distinguishing patients at a lower than
average risk versus those who are at a higher than average risk for
chemotherapy toxicity (Appendix Figs A2 and A3, online only,
Appendix Tables A1 and A2, online only). In addition, the area
under the ROC was slightly attenuated in the current study;
Table 3. Geriatric Assessment and Laboratory Values: Development and
Validation Cohorts
Variable
Development
Cohort
Validation
Cohort P
Functional status
MOS-ADL, mean (SD) 68.5 (26) 64.9 (27) .10
IADL, mean (SD) 12.9 (2) 13 (2) .67
PKPS, mean (SD) 85.6 (14) 84.7 (14) .50
MDKPS, mean (SD) 84.7 (11) 85.8 (13) .50
Falls, No. (%)
0 407 (82) 196 (78) .32
$ 1 91 (18) 54 (22)
Mean (SD) 0.3 (0.8) 0.4 (2.3)
Nutritional status
Body mass index, mean (SD) 26.2 (5) 26.7 (5) .14
Percent unintentional weight loss in
last 6 months, No. (%)
# 6% 328 (66) 178 (72)
. 6% 170 (34) 70 (28)
Mean (SD) 4.7 (6) 4.0 (6) .13
No. of comorbid conditions, No. (%)
0 48 (10) 16 (6) .08
1 110 (22) 40 (16)
2 121 (24) 67 (27)
$ 3 221 (44) 126 (51)
Cognition, No. (%)
Blessed Orientation–Memory
Concentration test score $ 11
29 (5.8) 16 (6.5) .74
Psychological state, mean (SD)
Hospital anxiety and depression scale 8.3 (6) 8.2 (6) .84
Social support, mean (SD)
MOS-social activity survey 56.2 (23) 60.3 (22) .02
MOS-social support survey 84.9 (21) 84.2 (21) .79
Laboratory value
WBC (k/mL), mean (SD) 7.9 (4) 7.5 (3) .08
Albumin (g/dL), mean (SD) 3.8 (0.5) 3.9 (0.5) .87
Hemoglobin (,11 g/dL [male],
, 10 g/dL [female]), No. (%)
62 (12) 33 (13) .83
Creatinine clearance ([Jelliffe, ideal
weight] , 34 mL/min), No. (%)
44 (9) 15 (6) .14
Abnormal liver function tests,
No. (%)
267 (56) 66 (26) , .01
Abbreviations: ADL, activities of daily living; IADL, instrumental activities of daily
living; MDKPS, Karnofsky physician-rated performance status; MOS, Medical
Outcomes Study; PKPS, Karnofksy self-reported performance status; SD,
standard deviation; WBC, white blood cell count.
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however, this was not statistically different. A decrease of 0.07
points in the area under the ROC from development to validation
has been described in the statistical literature as within an expected
range.27 There were some differences in patient characteristics
between the two cohorts that may explain part of the decrease in
the area under the ROC. Furthermore, we only predicted grade 3 to
5 toxicity, but grade 2 toxicity may be equally important in this
older population. Patients included in this cohort had solid tumors
and did not receive biologics or high-dose chemotherapy; there-
fore, these results primarily apply to patients with solid tumors
who receive chemotherapy. Finally, to use the model in other
populations, such as in countries outside of the United States or in
patients with different cancer types, additional external validation
studies must be performed.
This study has some major strengths as well. This study fills
a gap in knowledge by providing evidence of external validation of
a prediction model that is needed to demonstrate generalizability
of results and support translation of research into practice. Fur-
thermore, this model was validated in a prospective cohort of
patients seen in daily practice at eight institutions across the United
States, which increases the generalizability of the data. The pre-
diction model is easy to use, thus increasing the feasibility of
incorporation in daily practice, and the model can provide patients
and oncologists with additional information to be included in the
decision making process. Discussing the risks of treatment is es-
sential to enable patients to make a well-informed decision re-
garding treatment. Moreover, it may enable oncologists to anticipate
toxicity in patients with a high risk and to take preventive measures
to try to decrease this risk.
There are a number of future directions for this research. First,
toxicity may depend on the specific treatment. Hence, there are
several new ongoing, multicenter studies evaluating the efficacy of
this tool in predicting toxicity among patients with specific tumor
types and treatment regimens. To decrease the impact of che-
motherapy toxicity in older adults with cancer, future studies
should assess how the trajectory of toxicity can be changed. In
Table 4. Toxicity in Development Cohort and Validation Cohorts
Toxicity Type
Development Cohort Validation Cohort
Grade 3 to 5 Grade 3 Grade 4 Grade 5 Grade 3 to 5 Grade 3 Grade 4 Grade 5
Hematologic and Nonhematologic 265 (53) 197 (39) 58 (12) 10 (2) 145 (58) 132 (53) 38 (15) 6 (2)
Hematologic 131 (26) 90 (18) 39 (8) 2 (0) 86 (34) 58 (23) 26 (10) 2 (1)
ANC 57 (11) 40 (8) 17 (3) 0 (0) 51 (20) 31 (12) 20 (8) 0 (0)
WBC 49 (10) 41 (8) 8 (2) 0 (0) 4 (2) 4 (2) 0 (0) 0 (0)
Hemoglobin 48 (10) 45 (9) 3 (1) 0 (0) 20 (8) 18 (7) 2 (1) 0 (0)
Platelets 25 (5) 14 (3) 11 (2) 0 (0) 6 (2) 4 (2) 2 (1) 0 (0)
Infection with abnormal ANC 10 (2) 7 (1) 1 (0) 2 (0) 7 (3) 6 (2) 1 (0) 1 (0)
Nonhematologic 217 (43) 184 (37) 25 (5) 8 (2) 132 (55) 110 (44) 17 (7) 5 (2)
Fatigue 81 (16) 79 (16) 2 (0) 0 (0) 53 (21) 49 (20) 2 (1) 0 (0)
Infection with normal ANC 48 (10) 40 (8) 5 (1) 3 (1) 27 (11) 24 (10) 2 (1) 1 (0)
Dehydration 43 (9) 41 (8) 2 (0) 0 (0) 12 (5) 11 (4) 1 (0) 0 (0)
Thrombosis/embolism 22 (4) 17 (3) 4 (1) 1 (0) 6 (2) 2 (1) 3 (2) 0 (0)
Hyponatremia 22 (4) 22 (4) 0 (0) 0 (0) 5 (2) 5 (2) 0 (0) 0 (0)
Diarrhea 22 (4) 19 (4) 3 (1) 0 (0) 9 (4) 7 (3) 2 (1) 0 (0)
Hypokalemia 15 (3) 15 (3) 0 (0) 0 (0) 1 (0) 1 (0) 0 (0) 0 (0)
Dyspnea 13 (3) 5 (1) 7 (0) 1 (0) 4 (2) 3 (1) 1 (0) 0 (0)
Syncope 13 (3) 13 (3) 0 (0) 0 (0) 4 (2) 4 (2) 0 (0) 0 (0)
Neuropathy 13 (3) 13 (3) 0 (0) 0 (0) 9 (4) 9 (4) 0 (0) 0 (0)
Nausea 12 (2) 12 (2) 0 (0) 0 (0) 11 (4) 10 (4) 1 (0) 0 (0)
NOTE. Data are given as No. (%).
Abbreviations: ANC, absolute neutrophil count; WBC, white blood cell count.
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Fig 1. Risk strata versus toxicity percentage for the (A) development and (B)
validation cohorts.
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particular, studies are underway to determine whether geriatric
assessment targeted interventions can decrease chemotherapy
toxicity and improve functional outcomes and quality of life in
older adults with cancer (ClinicalTrials.gov: #NCT02054741).
Furthermore, studies are needed to understand how geriatric as-
sessment and toxicity prediction results should impact treatment
regimen, dosing, and supportive care. Impact of treatment toxicity
risk on doctor and patient treatment preferences and decisions
must be evaluated. Finally, the role of this tool in non-
chemotherapy regimens, that is, targeted therapy, and among
patients with hematologic malignancies is an area of needed
investigation.
In conclusion, this external validation study confirms that it is
possible to predict chemotherapy toxicity in older adults with
cancer by using a prediction model that consists of 11 questions,
including five geriatric assessment questions and six items captured
in routine daily practice—tumor type, treatment, and laboratory
values. These data should be considered when the risks and benefits
of chemotherapy are discussed in older adults. Future studies
should assess possible interventions that can decrease the risk of
toxicity in older adults with cancer.
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Appendix
The following institutions participated in the development cohort:
City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA
University of Rochester Medical Center, Rochester, NY
Upstate Medical University and Syracuse VA Medical Center, Syracuse, NY
Wake Forest University, Winston Salem, NC
Yale University, New Haven, CT
Case Western Reserve University, Cleveland, OH
Memorial Sloan Kettering Cancer Center, New York, NY
The following institutions participated in the validation cohort:
City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA
University of Rochester Medical Center, Rochester, NY
Upstate Medical University and Syracuse VA Medical Center, Syracuse, NY
Wake Forest University, Winston Salem, NC
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
Memorial Sloan Kettering Cancer Center, New York, NY
Case Western Reserve University, Cleveland, OH
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Fig A1. Receiver-operating characteristic curves for development and validation cohorts.
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Fig A2. Low risk versus combining medium and high-risk scores for the de-
velopment cohort.
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Fig A3. Low risk versus combining medium and high-risk scores for the vali-
dation cohort.
Table A1. Summary Statistics for Development Cohort
Risk Strata Mean Median SD Range
Low 3.9 4 1.0 0-5
High 8.7 8 2.5 6-19
Abbreviation: SD, standard deviation.
Table A2. Summary Statistics for Validation Cohort
Risk Strata Mean Median SD Range
Low 3.7 4 1.3 0-5
High 8.7 8 2.6 6-18
Abbreviation: SD, standard deviation.
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